Understanding how EWS-FLI1 oncogene affects cell growth in Ewing sarcoma
Official title: Mechanisms underlying USP1-mediated bypass of EWS-FLI1 oncogene-induced replication stress in Ewing sarcoma
Funded at University of Nebraska Medical Center · NIH-10894628 · Data updated 2026-11-12
This study is looking at how a specific gene in Ewing sarcoma cells helps them grow uncontrollably by avoiding the usual ways that cells fix their damaged DNA, and it hopes to find new treatment options that could help patients with this type of bone cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $333,575 |
| NIH project number | 5R01CA263504-03 |
| Project ID | NIH-10894628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Ewing sarcoma, particularly those with high levels of the EWS-FLI1 oncogene.
✕Less likely to help
Patients with other types of cancers or those without the EWS-FLI1 oncogene may not benefit from this research.
What this research studies
This research investigates the mechanisms by which the EWS-FLI1 oncogene causes replication stress in Ewing sarcoma, a type of bone cancer. It focuses on how cancer cells bypass the normal DNA damage response that would typically stop their growth, leading to uncontrolled cell proliferation. By studying the role of the USP1 protein, which is found to be overexpressed in Ewing sarcoma cells, the research aims to uncover new therapeutic targets that could improve treatment outcomes for patients. The approach combines basic science with potential clinical applications, providing insights into the disease's progression.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target the mechanisms of Ewing sarcoma, potentially improving survival rates.
How similar studies have gone: While the specific mechanisms of USP1 in Ewing sarcoma are being explored, similar research has shown promise in understanding oncogene-induced replication stress in other cancers.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Ghosal, Gargi — University of Nebraska Medical Center
- Study coordinator: Ghosal, Gargi
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.